Silver Book Fact

Cost-effectiveness of flu vaccine

Vaccination for pandemic influenza (pH1N1) prior to an outbreak produces incremental cost-effectiveness ratios for individuals without high risk conditions, ranging from $8,000 to $52,000 per quality-adjusted life year.

Prosser, Lisa A., Tara A. Lavelle, Anthony E. Fiore, Carolyn B. Bridges, Carrie Reed, et al. Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States. PLoS ONE. 2011; 6(7). http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0022308

Reference

Title
Cost-Effectiveness of 2009 Pandemic Influenza A (H1N1) Vaccination in the United States
Publication
PLoS ONE
Publication Date
2011
Authors
Prosser, Lisa A., Tara A. Lavelle, Anthony E. Fiore, Carolyn B. Bridges, Carrie Reed, et al.
Volume & Issue
Volume 6, Issue 7
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Vaccines in development 2013
    Vaccines in development for 2013  
  • Life years saved from infectious disease eradication
    Infectious disease eradication in the U.S. led to the following annual life years saved (LYS): 5,811,852 for measles 42,702 for tetanus 212,690 for polio 1,685,740 for smallpox  
  • Staff flu vaccination reduces incidence of staff and patients
    Vaccination of staff in a tertiary care facility over a period of 12 influenza seasons increased vaccination coverage from 4% to 67%, reduced laboratory-confirmed cases of influenza amongst staff from…  
  • Pertussis vaccination reduced global cases
    Vaccination helped reduce global pertussis (whooping cough) cases from 3 million per year to less 250,000.  
  • Mortality from vaccine-preventable diseases
    Vaccine-preventable diseases or their complications account for 50,000 to 90,000 adult deaths in the U.S. each year.